usdaed

Here are three stocks to double down on now. Their recent dips are like that friend who yells “SALE!” at their garage sale-overly dramatic but maybe worth a glance.

Now, a 500% increase year-to-date, a tenfold jump from the depths of despair in June-one might think it an invitation to hope. But the cold, indifferent market cap of $7 billion, with its stock priced at a mere $9.50 as of September 15, mocks any sense of coherent judgment. Even at this modest valuation, Opendoor remains below its debut price-after merging with a special purpose acquisition company (SPAC)-as though all that has occurred is an elaborate form of futility, the company stumbling blindly through a marketplace that demands precision.

Archer’s aircraft, these so-called “sky-scooters,” are meant to zip between cities like drowsy bees. The notion may seem as sensible as teaching a cat to dance, yet the company claims a market worth a trillion dollars-enough to make even the greediest of goblins weep with delight. But here’s the catch: the price of a share is less than a loaf of bread. A bargain? Or a trap set by a mischievous squirrel?

Let us not mince words: retail is a realm where margins are as thin as the paper upon which they are inked. Yet Costco, with its gilded trinity of Amazon, Walmart, and itself, has mastered the art of the illusion. They prance about, ever the industrious ants, yet their truest muse is the alchemy of turning pennies into gold.

Enter CoreWeave (CRWV)-the current darling of the GPU world, although one might rather imagine it as the scruffy debutante in a glittering ballroom. Nvidia has cast its gaze toward CoreWeave with a hefty, multibillion-dollar investment, clearly signaling that this charming new acquaintance has piqued its interest, at least temporarily.

The Bitcoinian ascent, after a brief lull in August, has resumed its dance with the Federal Reserve’s rate cut-a key turned in the lock of a vault long sealed. Yet this is but one of many doors. Analyst Michael Donovan of Compass Point, a chronicler of mining ventures, has etched his judgment in the margins: a “buy” at $8 per share, as if deciphering a cipher hidden in the company’s balance sheet.

Cantor Fitzgerald’s Andres Sheppard, a man who seems to speak in riddles and stock tips, gave EVgo another nod before the week began. He declared it a “buy” and set a price target so lofty it might as well have been written in a foreign language. That $7 mark, he claimed, would grant investors a 51% boost-a return that would make even a penny-pincher’s eyes widen.

The spark? A $5 billion investment from Nvidia-a deal so large it makes you wonder if the check was printed in Comic Sans to fit the page. The agreement, dubbed a “multigeneration partnership,” involves Intel crafting custom CPUs for Nvidia’s AI data centers, while Nvidia lends a hand (or a GPU) to spruce up Intel’s PC offerings. It’s the semiconductor equivalent of two giants trading hats and pretending it’s a business strategy.

The stock has bounced up and down like a toddler on a sugar rush, spiking nearly 90% last week before taking a breather. Investors, in their infinite wisdom, are trying to figure out what this chip company might actually be worth after emerging from bankruptcy. Because, of course, bankruptcy is where all the exciting corporate drama happens, right?

The fateful summit with regulators occurred on Tuesday, where Replimune’s RP1-a cancer drug partnered with Bristol Myers Squibb‘s Opdivo-was dissected with the precision of a surgeon and the enthusiasm of a tax audit. The June “complete response letter” from the FDA had already cast a shadow over the drug’s prospects, but this meeting merely confirmed what seasoned investors have always known: hope is a poor substitute for due diligence.